New and re-emerging infectious diseases

36. New and re-emerging infectious diseases




There has been considerable success in combating infection in the developed world since the middle of the last century, through advances in nutrition and hygiene as well as the development of drugs and vaccines. The worldwide eradication of smallpox was a notable success. However, despite many improvements there are still 15 million (> 25%) deaths worldwide attributable to infectious diseases (Fig. 3.36.1). ‘New’ infections are constantly being described (Appendix, Table A.2), and there is always the problem of established infections becoming resistant to current therapies (Table 3.36.1).



Table 3.36.1 EMERGING PROBLEMS OF DRUG RESISTANCE










































Infectious agent Resistance problem
Herpes simplex virus Aciclovir
Human immunodeficiency virus Zidovudine and others
Methicillin-resistant Staphylococcus aureus (MRSA) β-Lactams (and other antibiotics)
Vancomycin-resistant S. aureus (VISA or VRSA) Methicillin; now also resistant to vancomycin
Penicillin-resistant Streptococcus pneumoniae β-Lactams (and other antibiotics)
Neisseria gonorrhoeae Penicillin, tetracycline, quinolones
Glycopeptide-resistant Enterococcus spp. (GRE) Multiresistance, including to glycopeptides
Multidrug-resistant Mycobacterium tuberculosis (MDR-TB) Isoniazid, pyrazinamide, rifampicin and others
Gram-negative organisms with ‘extended spectrum β-lactamases’ (ESBL) β-Lactams (and other antibiotics)
Candida spp. Fluconazole
Plasmodium spp. Chloroquine
Scabies Lindane

Stay updated, free articles. Join our Telegram channel

Jul 3, 2016 | Posted by in MUSCULOSKELETAL MEDICINE | Comments Off on New and re-emerging infectious diseases

Full access? Get Clinical Tree

Get Clinical Tree app for offline access